Arrowhead Pharmaceuticals (ARWR) Stock
Clinical stage biotech developing gene silencing liver drugs. Here's the price, business snapshot, and what's worth knowing about Arrowhead Pharmaceuticals in August 2026.
Arrowhead Pharmaceuticals (ARWR) is a clinical-stage biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. Using a proprietary delivery platform designed to silence specific genes, Arrowhead advances candidates aimed primarily at liver-related diseases and other conditions where gene knockdown may be therapeutic. The business model is R&D‑driven: value tends to be tied to clinical milestones, regulatory progress and partnerships rather than stable product revenue. Investors should note the binary nature of clinical outcomes, the time and capital typically required to bring experimental therapies to market, and the potential for significant share-price volatility around trial results and deal announcements. The company may partner or licence programmes to larger pharmaceutical groups to share development risk and access commercial expertise. This summary is for educational purposes only and not investment advice; individual suitability depends on personal circumstances and risk tolerance.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arrowhead Pharmaceuticals' stock, expecting it to rise in value soon.
Financial Health
Arrowhead Pharmaceuticals is performing well with good revenue and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage pipeline
Progress in human trials can materially change valuation, so clinical read-outs are worth watching — though outcomes are binary and can be unpredictable.
RNAi platform focus
A platform approach can create multiple opportunities if delivery and safety perform well, but technical and regulatory hurdles remain.
Partnerships and deals
Collaborations with larger pharma can de‑risk development and provide milestones, yet deal terms and reliance on partners also shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
